Auro Laboratories Limited has submitted the Outcome of Board Meeting held on 12th November, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Auro Laboratories' board approved unaudited results for Q2 FY26 and H1 FY26 on November 12, 2025. Q2 FY26 revenue from operations surged roughly 185% year-on-year to ₹883.67 lakhs from ₹310.12 lakhs, while Q2 profit after tax nearly doubled to ₹71.58 lakhs from ₹35.81 lakhs, lifting EPS to ₹1.45 from ₹0.57. However, the H1 FY26 picture is weaker: revenue grew about 25% to roughly ₹1,101 lakhs but H1 PAT fell around 45% to ₹61.03 lakhs versus ₹111.08 lakhs last year, dragged down by a small loss in Q1 FY26. The statutory auditor B.L. Dasharda & Associates issued a clean limited review report with no qualifications or emphasis of matter. Total assets rose to ₹11,077 lakhs with borrowings of about ₹4,394 lakhs against equity of ₹4,358 lakhs, keeping debt-equity near 1x.
Sharp Q2 rebound signals an operational recovery and may support the stock, but the weak H1 bottom line and elevated leverage mean investors should watch whether the Q2 momentum sustains into the second half.